Sanofi (SASY.PA) sees a strong strategic fit with Medivation (MDVN.O) even though its tie-up proposal was rejected by the U.S. cancer drug maker last week, the company's chief executive said on Wednesday.
The French drugmaker went public with a $9.3 billion proposal to buy Medivation on April 28 but the target said offer undervalued the company and its pipeline of drugs.
U.S firm Pfizer (PFE.N) has also approached Medivation to express interest in an acquisition, raising the possibility of a bid rivaling Sanofi's, people familiar with the matter said on Tuesday.
The French drugmaker went public with a $9.3 billion proposal to buy Medivation on April 28 but the target said offer undervalued the company and its pipeline of drugs.
U.S firm Pfizer (PFE.N) has also approached Medivation to express interest in an acquisition, raising the possibility of a bid rivaling Sanofi's, people familiar with the matter said on Tuesday.
